And so, another working week will soon draw to a close. Not a moment too soon, yes?
This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda, so far, is very low-key.
We hope to catch up on our reading, promenade with the official mascots, and take a few naps. We may also manicure the Pharmalot grounds.
And of course, we hope to hold still another listening party, where the rotation will likely include this , this , this , this and this . And what about you?
The choices are endless this time of year. In particular, the great outdoors are beckoning — trails can be hiked, streets can be walked, country roads can be driven.
If this fails, there is always the great indoors. You could cook a fabulous meal, shop for something that looks spiffy, or binge watch on the telly.
Or you could be totally zen and do absolutely nothing. Well, whatever you prefer, have a grand time.
But be safe. Enjoy, and see you soon… A U.S.
STAT News published a clinical update in Research Highlights on 29 May 2026.
The item focuses on STAT+: Pharmalittle: We’re reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and more.
Review the original article for the full source wording and details.